Meclizine Hydrochloride


Apnar Pharma Lp
Human Otc Drug
NDC 24689-138
Meclizine Hydrochloride is a human otc drug labeled by 'Apnar Pharma Lp'. National Drug Code (NDC) number for Meclizine Hydrochloride is 24689-138. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Meclizine Hydrochloride drug includes Meclizine Hydrochloride - 12.5 mg/1 . The currest status of Meclizine Hydrochloride drug is Active.

Drug Information:

Drug NDC: 24689-138
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Meclizine Hydrochloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Meclizine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Apnar Pharma Lp
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:MECLIZINE HYDROCHLORIDE - 12.5 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 29 Jul, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: M009
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:APNAR PHARMA LP
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:995624
995666
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0324689138015
0324689139012
UPC stands for Universal Product Code.
UNII:HDP7W44CIO
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Antiemetic [EPC]
Emesis Suppression [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
24689-138-01100 TABLET in 1 BOTTLE (24689-138-01)29 Jul, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose antiemetic

Product Elements:

Meclizine hydrochloride meclizine hydrochloride meclizine hydrochloride meclizine magnesium stearate silicon dioxide lactose monohydrate microcrystalline cellulose a;c4 meclizine hydrochloride meclizine hydrochloride silicon dioxide meclizine hydrochloride meclizine microcrystalline cellulose magnesium stearate lactose monohydrate white to off white am7

Boxed Warning:

Tamper evident: do not use if safety seal is broken or missing

Indications and Usage:

Uses prevents and treats nausea, vomiting or dizziness associated with motion sickness

Warnings:

Do not use in children under 12 years of age unless directed by a doctor do not take this product, unless directed by a doctor, if you have glaucoma a breathing problem such as emphysema or chronic bronchitis trouble urination due to an enlarged prostate gland do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor. when using this product, do not exceed recommended dosage may cause drowsiness alcohol, sedatives and tranquilizers may increase drowsiness avoid alcoholic drinks use caution when driving a motor vehicle or operating machinery if pregnant or breast-feeding, ask a health professional before use

Dosage and Administration:

Directions meclizine hcl 12.5mg tablet : dosage should be taken one hour before travel starts -adults & children 12 years and over: take 2 or 4 tablets once daily or as directed by a doctor meclizine hcl 25mg tablet: dosage should be taken one hour before travel starts -adults & children 12 years and over: take 1 or 2 tablets once daily or as directed by a doctor

Package Label Principal Display Panel:

Ndc : 24689-138-01 meclizine hydrochloride tablets 12.5 mg antiemetic 100 tablets ndc : 24689-139-01 meclizine hydrochloride tablets 25 mg antiemetic 100 tablets meclizine hcl 12.5 mg tablets -100s meclizine hcl 25 mg _label-100s

Further Questions:

Questions or comments? call 1-855-642-2594


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.